A Breakthrough in the Fight Against a Rare Disease: Researchers have pinpointed a potential drug target for Friedreich’s ataxia (FA), a devastating genetic disorder, opening new doors for treatment. Imagine a condition that often strikes between ages 5 and 15, with a life expectancy only into the 30s or 40s. This is the harsh reality of FA, but there's hope on the horizon!
Scientists from Mass General Brigham and the Broad Institute have made a groundbreaking discovery that could lead to new medicines. Their work focuses on a genetic modifier of the disease, providing a crucial insight for developing effective therapies. Their findings were published in Nature.
To understand FA better, researchers used model organisms, including tiny roundworms called C. elegans. These humble creatures played a key role in unraveling the complexities of this disease. In fact, their results were validated by an independent research group's biochemical analysis, also published in Nature.
FA is caused by a deficiency of frataxin, a vital mitochondrial protein involved in producing iron-sulfur clusters. These clusters are essential for cellular energy production. Previous research showed that low oxygen (hypoxia) could partially compensate for the lack of frataxin in human cells, worms, and mice.
"Instead of using hypoxia as a direct therapy, we used it as a clever trick to find genetic suppressors," explains lead author Joshua Meisel, now an assistant professor at Brandeis University. He notes that the identified suppressor, FDX2, is a protein that can be targeted with existing medications.
To explore how cells could overcome frataxin loss, the team, including Nobel laureate Gary Ruvkun, used C. elegans as a model. They created worms without frataxin and grew them in low-oxygen conditions, allowing them to survive. Then, they introduced random genetic changes, searching for rare worms that could thrive even in normal oxygen levels.
By sequencing the genomes of these survivors, the scientists identified mutations in two mitochondrial genes: FDX2 and NFS1. They confirmed the effects of these mutations through advanced genetic engineering, biochemical tests, and experiments in human cells and mice.
The study revealed that specific mutations in FDX2 and NFS1 can bypass the need for frataxin, enabling cells to produce iron-sulfur clusters even when frataxin is missing. Reducing FDX2 levels, either through genetic mutation or by removing one copy of the gene, restored iron-sulfur cluster synthesis and improved cell health.
"The balance between frataxin and FDX2 is key," says senior author Vamsi Mootha. "When there's too little frataxin, reducing FDX2 helps. It's a delicate balancing act to ensure proper biochemical homeostasis."
But here's where it gets controversial... Lowering FDX2 levels in a mouse model of FA improved neurological symptoms, hinting at a new treatment strategy. This suggests that adjusting the levels of proteins that interact with frataxin could counteract the effects of its loss in the disease.
And this is the part most people miss... The researchers emphasize that the ideal balance of frataxin and FDX2 may vary, and more research is needed to understand how this balance is regulated in humans. Future studies will determine if adjusting FDX2 levels is safe and effective before human trials are considered.
What do you think? Could this be the beginning of a new era in FA treatment? Do you think it's wise to focus on manipulating gene expression? Share your thoughts in the comments!
Authorship: In addition to Meisel, Mootha and Ruvkun, authors include Pallavi R. Joshi, Amy N. Spelbring, Hong Wang, Sandra M. Wellner, Presli P. Wiesenthal, Maria Miranda, Jason G. McCoy, and David P. Barondeau.
Disclosures: Mootha is listed as an inventor on patents filed by MGH on therapeutic uses of hypoxia. Meisel, Ruvkun, and Mootha are listed as inventors on a patent filed by MGH on technology reported in this paper; Meisel, Ruvkun, and Mootha own equity in and are paid advisors to Falcon Bio, a company focusing on this technology. Mootha is a paid advisor to 5am Ventures.
Funding: This work was supported in part by the Friedreich’s Ataxia Research Alliance, the National Institutes of Health (R00GM140217, R01NS124679, R01AG016636, and R01GM096100), and the Robert A. Welch Foundation (A-1647). Meisel was supported by The Jane Coffin Childs Memorial Fund for Medical Research. Miranda was supported by the Deutsche Forschungsgemeinschaft (431313887). Mootha is an Investigator of the Howard Hughes Medical Institute.
Paper cited: Meisel Jet al.“Mutations in mitochondrial ferredoxin FDX2 suppress frataxin deficiency” Nature DOI: 10.1038/s41586-025-09821-2
About the Broad Institute: The Broad Institute is an independent, non-profit research organization dedicated to understanding the roots of disease and bridging the gap between scientific insights and patient impact. Founded in 2004 by Eli and Edythe Broad, it brings together scientists from diverse fields, including genomics, cell biology, and computational biology. The Broad Institute collaborates with thousands of scientists from various institutions and industries to translate research findings into effective therapies for both common and rare diseases.
